

John R Perfect

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6578919/publications.pdf>

Version: 2024-02-01

253
papers

24,601
citations

14614

66
h-index

8138

148
g-index

280
all docs

280
docs citations

280
times ranked

18874
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375
2	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 291-322.	2.9	2,195
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
4	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. <i>New England Journal of Medicine</i> , 2009, 361, 1760-1767.	13.9	671
5	Voriconazole Treatment for Less Common, Emerging, or Refractory Fungal Infections. <i>Clinical Infectious Diseases</i> , 2003, 36, 1122-1131.	2.9	643
6	<i>Cryptococcus neoformans</i> . , 1998, , .		642
7	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	4.6	586
8	The antifungal pipeline: a reality check. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 603-616.	21.5	574
9	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
10	Combination Antifungal Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 693-715.	1.4	478
11	Resistance to Antifungal Agents: Mechanisms and Clinical Impact. <i>Clinical Infectious Diseases</i> , 2008, 46, 120-128.	2.9	473
12	Cryptococcosis. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 179-206.	1.9	473
13	Urease as a Virulence Factor in Experimental Cryptococcosis. <i>Infection and Immunity</i> , 2000, 68, 443-448.	1.0	459
14	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	2.9	368
15	Cryptococcosis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 837-874.	1.9	354
16	Analysis of the Genome and Transcriptome of <i>Cryptococcus neoformans</i> var. <i>grubii</i> Reveals Complex RNA Expression and Microevolution Leading to Virulence Attenuation. <i>PLoS Genetics</i> , 2014, 10, e1004261.	1.5	336
17	Extracellular phospholipase activity is a virulence factor for <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2001, 39, 166-175.	1.2	319
18	Cyclic AMP-Dependent Protein Kinase Controls Virulence of the Fungal Pathogen <i>Cryptococcus neoformans</i> . <i>Molecular and Cellular Biology</i> , 2001, 21, 3179-3191.	1.1	310

#	ARTICLE	IF	CITATIONS
19	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017, 2, .	1.3	274
20	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. <i>Lancet Microbe</i> , 2022, 3, e543-e552.	3.4	255
21	Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 952-958.	1.4	212
22	RAS1 regulates filamentation, mating and growth at high temperature of <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2000, 36, 352-365.	1.2	211
23	Cryptococcosis diagnosis and treatment: What do we know now. <i>Fungal Genetics and Biology</i> , 2015, 78, 49-54.	0.9	194
24	CX3CR1-dependent renal macrophage survival promotes <i>Candida</i> control and host survival. <i>Journal of Clinical Investigation</i> , 2013, 123, 5035-5051.	3.9	190
25	Azole antifungals: 35 years of invasive fungal infection management. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 787-798.	2.0	179
26	Morphologic Criteria for the Preliminary Identification of <i>Fusarium</i> , <i>Paecilomyces</i> , and <i>Acremonium</i> Species by Histopathology. <i>American Journal of Clinical Pathology</i> , 1998, 109, 45-54.	0.4	177
27	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. <i>Clinical Infectious Diseases</i> , 2016, 63, 356-362.	2.9	167
28	Comparison and Temporal Trends of Three Groups with Cryptococcosis: HIV-Infected, Solid Organ Transplant, and HIV-Negative/Non-Transplant. <i>PLoS ONE</i> , 2012, 7, e43582.	1.1	161
29	Protection against Cryptococcosis by Using a Murine Gamma Interferon-Producing <i>Cryptococcus neoformans</i> Strain. <i>Infection and Immunity</i> , 2007, 75, 1453-1462.	1.0	160
30	Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calciressin, in <i>Cryptococcus neoformans</i> . <i>EMBO Journal</i> , 2000, 19, 3618-3629.	3.5	158
31	Functional genomics identifies type I interferon pathway as central for host defense against <i>Candida albicans</i> . <i>Nature Communications</i> , 2013, 4, 1342.	5.8	157
32	Fungi that Infect Humans. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	149
33	Metabolic adaptation in <i>Cryptococcus neoformans</i> during early murine pulmonary infection. <i>Molecular Microbiology</i> , 2008, 69, 1456-1475.	1.2	147
34	Plasminogen Alleles Influence Susceptibility to Invasive Aspergillosis. <i>PLoS Genetics</i> , 2008, 4, e1000101.	1.5	145
35	Characterization and Regulation of the Trehalose Synthesis Pathway and Its Importance in the Pathogenicity of <i>Cryptococcus neoformans</i> . <i>Infection and Immunity</i> , 2006, 74, 5877-5887.	1.0	144
36	Treatment of Non-Aspergillus Moulds in Immunocompromised Patients, with Amphotericin B Lipid Complex. <i>Clinical Infectious Diseases</i> , 2005, 40, S401-S408.	2.9	142

#	ARTICLE	IF	CITATIONS
37	Antifungal Resistance Trends Towards the Year 2000. <i>Drugs</i> , 1997, 54, 657-678.	4.9	140
38	The STE12 ^Δ Homolog Is Required for Haploid Filamentation But Largely Dispensable for Mating and Virulence in <i>Cryptococcus neoformans</i> . <i>Genetics</i> , 1999, 153, 1601-1615.	1.2	138
39	ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. <i>Mycoses</i> , 2021, 64, 1028-1037.	1.8	137
40	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. <i>Journal of Infectious Diseases</i> , 2017, 216, S474-S483.	1.9	135
41	Population genomics and the evolution of virulence in the fungal pathogen <i>Cryptococcus neoformans</i> . <i>Genome Research</i> , 2017, 27, 1207-1219.	2.4	134
42	Titan cells formation in <i>Cryptococcus neoformans</i> is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. <i>PLoS Pathogens</i> , 2018, 14, e1006982.	2.1	119
43	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. <i>Journal of Infectious Diseases</i> , 2012, 205, 934-943.	1.9	116
44	The <i>Cryptococcus neoformans</i> Transcriptome at the Site of Human Meningitis. <i>MBio</i> , 2014, 5, e01087-13.	1.8	113
45	Tracing Genetic Exchange and Biogeography of <i>Cryptococcus neoformans</i> var. <i>grubii</i> at the Global Population Level. <i>Genetics</i> , 2017, 207, 327-346.	1.2	105
46	Trehalose 6-phosphate phosphatase is required for cell wall integrity and fungal virulence but not trehalose biosynthesis in the human fungal pathogen <i>Aspergillus fumigatus</i> . <i>Molecular Microbiology</i> , 2010, 77, 891-911.	1.2	104
47	Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5758-5765.	1.4	99
48	Drug resistance in <i>Cryptococcus neoformans</i> . <i>Drug Resistance Updates</i> , 1999, 2, 259-269.	6.5	95
49	Intracellular Action of a Secreted Peptide Required for Fungal Virulence. <i>Cell Host and Microbe</i> , 2016, 19, 849-864.	5.1	93
50	Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. <i>Microbiology and Molecular Biology Reviews</i> , 2017, 81, .	2.9	93
51	<i>Cryptococcus neoformans</i> : A sugar-coated killer with designer genes. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 45, 395-404.	2.7	92
52	<i>In Vitro</i> and <i>In Vivo</i> Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against <i>Cryptococcus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	90
53	<i>Cryptococcus neoformans</i> Requires a Functional Glycolytic Pathway for Disease but Not Persistence in the Host. <i>MBio</i> , 2011, 2, e00103-11.	1.8	89
54	The Trehalose Synthesis Pathway Is an Integral Part of the Virulence Composite for <i>Cryptococcus gattii</i> . <i>Infection and Immunity</i> , 2009, 77, 4584-4596.	1.0	88

#	ARTICLE	IF	CITATIONS
55	Identification and characterization of the <i>Cryptococcus neoformans</i> phosphomannose isomerase-encoding gene, <i>MAN1</i> , and its impact on pathogenicity. <i>Molecular Microbiology</i> , 2001, 40, 610-620.	1.2	86
56	Fungal diagnosis: how do we do it and can we do better?. <i>Current Medical Research and Opinion</i> , 2013, 29, 3-11.	0.9	83
57	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	1.9	83
58	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	4.6	80
59	Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020, 70, 30-39.	2.9	79
60	Use of Antifungal Combination Therapy: Agents, Order, and Timing. <i>Current Fungal Infection Reports</i> , 2010, 4, 87-95.	0.9	76
61	The Impact of the Host on Fungal Infections. <i>American Journal of Medicine</i> , 2012, 125, S39-S51.	0.6	76
62	ImmunoChip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014, 5, 4675.	5.8	76
63	Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. <i>Annals of Internal Medicine</i> , 2019, 170, 845.	2.0	72
64	CXCR1-mediated neutrophil degranulation and fungal killing promote <i>Candida</i> clearance and host survival. <i>Science Translational Medicine</i> , 2016, 8, 322ra10.	5.8	71
65	Topoisomerase I Is Essential in <i>Cryptococcus neoformans</i> : Role in Pathobiology and as an Antifungal Target. <i>Genetics</i> , 1999, 152, 167-178.	1.2	71
66	Brain Inositol Is a Novel Stimulator for Promoting <i>Cryptococcus</i> Penetration of the Blood-Brain Barrier. <i>PLoS Pathogens</i> , 2013, 9, e1003247.	2.1	69
67	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against <i>Candida</i> infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 963-974.	1.3	69
68	Microevolution of Serial Clinical Isolates of <i>Cryptococcus neoformans</i> var. <i>grubii</i> and <i>C. Ágattii</i> . <i>MBio</i> , 2017, 8, .	1.8	69
69	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 502-510.	2.9	68
70	â€œIs there an emerging need for new antifungals?â€ Expert Opinion on Emerging Drugs, 2016, 21, 129-131.	1.0	68
71	Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion. <i>MBio</i> , 2015, 6, e01425-15.	1.8	65
72	Association of Plasma Levels of Human Immunodeficiency Virus Type 1 RNA and Oropharyngeal <i>Candida</i> Colonization. <i>Journal of Infectious Diseases</i> , 1999, 180, 534-537.	1.9	62

#	ARTICLE	IF	CITATIONS
73	Comparative analyses of clinical and environmental populations of <i>Cryptococcus neoformans</i> in Botswana. <i>Molecular Ecology</i> , 2015, 24, 3559-3571.	2.0	61
74	Adverse Drug Reactions to Systemic Antifungals Prevention and Management. <i>Drug Safety</i> , 1992, 7, 323-363.	1.4	60
75	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57
76	Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against <i>Candida albicans</i> . <i>PLoS ONE</i> , 2013, 8, e57672.	1.1	54
77	Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, S352-S355.	2.9	54
78	The war on cryptococcosis: A Review of the antifungal arsenal. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2018, 113, e170391.	0.8	54
79	Trehalose pathway as an antifungal target. <i>Virulence</i> , 2017, 8, 143-149.	1.8	53
80	A global call for talaromycosis to be recognised as a neglected tropical disease. <i>The Lancet Global Health</i> , 2021, 9, e1618-e1622.	2.9	52
81	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1268-1278.	2.9	51
82	Phenotypic Variability Correlates with Clinical Outcome in <i>Cryptococcus</i> Isolates Obtained from Botswanan HIV/AIDS Patients. <i>MBio</i> , 2018, 9, .	1.8	50
83	Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 559-586.	1.0	48
84	Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw261.	0.4	48
85	Survival Defects of <i>Cryptococcus neoformans</i> Mutants Exposed to Human Cerebrospinal Fluid Result in Attenuated Virulence in an Experimental Model of Meningitis. <i>Infection and Immunity</i> , 2010, 78, 4213-4225.	1.0	47
86	Inkjet Printing of Amphotericin B onto Biodegradable Microneedles Using Piezoelectric Inkjet Printing. <i>Jom</i> , 2013, 65, 525-533.	0.9	47
87	Fatty Acid Synthesis Is Essential for Survival of <i>Cryptococcus neoformans</i> and a Potential Fungicidal Target. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3537-3545.	1.4	46
88	Present and Future Therapy of <i>Cryptococcus</i> Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 79.	1.5	46
89	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7148-7153.	3.3	44
90	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019, 10, .	1.8	44

#	ARTICLE	IF	CITATIONS
91	Antisense repression in <i>Cryptococcus neoformans</i> as a laboratory tool and potential antifungal strategy. <i>Microbiology (United Kingdom)</i> , 2002, 148, 213-219.	0.7	44
92	Tolerability profile of the current antifungal armoury. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i26-i32.	1.3	41
93	Associations between <i>Cryptococcus</i> Genotypes, Phenotypes, and Clinical Parameters of Human Disease: A Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 260.	1.5	41
94	Blood Gene Expression Signatures Predict Invasive Candidiasis. <i>Science Translational Medicine</i> , 2010, 2, 21ra17.	5.8	40
95	Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. <i>Journal of Medical Microbiology</i> , 2018, 67, 215-227.	0.7	38
96	Human genetic susceptibility to <i>Candida</i> infections. <i>Medical Mycology</i> , 2012, 50, 785-794.	0.3	37
97	Copy number variation contributes to cryptic genetic variation in outbreak lineages of <i>Cryptococcus gattii</i> from the North American Pacific Northwest. <i>BMC Genomics</i> , 2016, 17, 700.	1.2	36
98	Next generation multilocus sequence typing (NGMLST) and the analytical software program MLST-EZ enable efficient, cost-effective, high-throughput, multilocus sequencing typing. <i>Fungal Genetics and Biology</i> , 2015, 75, 64-71.	0.9	34
99	Genetic Susceptibility to Fungal Infections: What is in the Genes?. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 81-91.	1.8	34
100	Genome-wide analysis of the regulation of Cu metabolism in <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2018, 108, 473-494.	1.2	34
101	Surfactant Protein D Facilitates <i>Cryptococcus neoformans</i> Infection. <i>Infection and Immunity</i> , 2012, 80, 2444-2453.	1.0	33
102	Regulation of cytochrome c oxidase subunit 1 (COX1) expression in <i>Cryptococcus neoformans</i> by temperature and host environment. <i>Microbiology (United Kingdom)</i> , 2003, 149, 1041-1049.	0.7	33
103	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	1.8	32
104	Taming Amphotericin B. <i>Bioconjugate Chemistry</i> , 2015, 26, 2021-2024.	1.8	31
105	<i>Cryptococcus neoformans</i> resists to drastic conditions by switching to viable but non-culturable cell phenotype. <i>PLoS Pathogens</i> , 2019, 15, e1007945.	2.1	31
106	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.	2.9	31
107	Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis. <i>Clinical Infectious Diseases</i> , 2021, 73, e330-e336.	2.9	29
108	Combination Therapy for Invasive Fungal Infections. <i>Current Fungal Infection Reports</i> , 2020, 14, 40-49.	0.9	29

#	ARTICLE	IF	CITATIONS
109	Cryptococcal meningoencephalitis: time for action. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e259-e271.	4.6	29
110	Deferoxamine Treatment as a Risk Factor for Zygomycete Infection. <i>Journal of Infectious Diseases</i> , 1989, 159, 151-152.	1.9	28
111	Design of Aerosolized Amphotericin B Formulations for Prophylaxis Trials among Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2004, 39, S207-S210.	2.9	28
112	The Zinc Finger Protein Mig1 Regulates Mitochondrial Function and Azole Drug Susceptibility in the Pathogenic Fungus <i>Cryptococcus neoformans</i> . <i>MSphere</i> , 2016, 1, .	1.3	28
113	Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 1147-1154.	1.9	28
114	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	27
115	Amoeba Predation of <i>Cryptococcus neoformans</i> Results in Pleiotropic Changes to Traits Associated with Virulence. <i>MBio</i> , 2021, 12, .	1.8	27
116	Structural and <i>In Vivo</i> Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. <i>MBio</i> , 2017, 8, .	1.8	26
117	Emerging Issues in Antifungal Resistance. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 921-943.	1.9	26
118	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With <i>Cryptococcus neoformans</i> or <i>Cryptococcus gattii</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, 1133-1141.	2.9	26
119	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	1.8	25
120	Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. <i>Emerging Microbes and Infections</i> , 2019, 8, 119-129.	3.0	25
121	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	25
122	Invasive Mycoses: Evolving Challenges and Opportunities in Antifungal Therapy (Multimedia Activity). <i>American Journal of Medicine</i> , 2011, 124, S2-S3.	0.6	24
123	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	1.8	24
124	Landscape of gene expression variation of natural isolates of <i>Cryptococcus neoformans</i> in response to biologically relevant stresses. <i>Microbial Genomics</i> , 2020, 6, .	1.0	24
125	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. <i>PLoS ONE</i> , 2017, 12, e0180824.	1.1	24
126	The Triple Threat of Cryptococcosis: It's the Body Site, the Strain, and/or the Host. <i>MBio</i> , 2012, 3, .	1.8	23

#	ARTICLE	IF	CITATIONS
127	Gene Expression of Diverse <i>Cryptococcus</i> Isolates during Infection of the Human Central Nervous System. <i>MBio</i> , 2021, 12, e0231321.	1.8	23
128	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 795-812.	1.9	23
129	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 276.	0.7	22
130	Repeated therapeutic lumbar punctures in cryptococcal meningitis – necessity and/or opportunity?. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 539-545.	1.3	21
131	New potential targets for antifungal development. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 265-296.	1.0	20
132	Environmental Niches for <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . , 0, , 235-259.		19
133	Fungal infections of the bones and joints. <i>Current Infectious Disease Reports</i> , 2001, 3, 450-460.	1.3	18
134	Molecular Typing of the <i>Cryptococcus neoformans</i> / <i>Cryptococcus gattii</i> Species Complex. , 2014, , 327-357.		18
135	Cases of disseminated cryptococcosis in intravenous drug abusers without HIV infection: A new risk factor?. <i>Medical Mycology Case Reports</i> , 2016, 14, 17-19.	0.7	18
136	Comparing outcomes of early, late, and non-surgical management of intraspinal abscess. <i>Journal of Clinical Neuroscience</i> , 2017, 36, 64-71.	0.8	17
137	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. <i>Journal of Infectious Diseases</i> , 2019, 220, 862-872.	1.9	17
138	Clinical Perspectives on <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> : Implications for Diagnosis and Management. , 0, , 595-606.		16
139	Cryptococcal Meningitis with Normal Cerebrospinal Fluid. <i>Journal of Infectious Diseases</i> , 1989, 160, 912-912.	1.9	15
140	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50,222 Td (m	1.3	14
141	Occult <i>Talaromyces marneffei</i> Infection Unveiled by the Novel Mp1p Antigen Detection Assay. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa502.	0.4	14
142	The virulence factor urease and its unexplored role in the metabolism of <i>Cryptococcus neoformans</i> . <i>FEMS Yeast Research</i> , 2020, 20, .	1.1	13
143	Systematics of the Genus <i>Cryptococcus</i> and Its Type Species <i>C. neoformans</i> . , 0, , 1-15.		12
144	Retrospective review of amphotericin B use in a tertiary-care medical center. <i>American Journal of Health-System Pharmacy</i> , 1987, 44, 1353-1357.	0.5	11

#	ARTICLE	IF	CITATIONS
145	Scedosporium apioserum infection of the "Native" valve: Fungal endocarditis in an orthotopic heart transplant recipient. Medical Mycology Case Reports, 2015, 9, 34-36.	0.7	11
146	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 493-500.	2.9	10
147	Simple Strategy for Taming Membrane-Disrupting Antibiotics. Bioconjugate Chemistry, 2016, 27, 2850-2853.	1.8	10
148	Pulmonary blastomycosis presenting as primary lung cancer. BMC Infectious Diseases, 2018, 18, 336.	1.3	10
149	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
150	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. Medical Mycology Case Reports, 2020, 27, 17-21.	0.7	10
151	The robust and rapid role of molecular testing in precision fungal diagnostics: A case report. Medical Mycology Case Reports, 2020, 27, 77-80.	0.7	10
152	Veterinary Insights into Cryptococcosis Caused by <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . , 0, , 489-504.		10
153	Human Cryptococcosis. , 0, , 407-456.		10
154	Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen Cryptococcus neoformans. MBio, 2021, 12, e0279021.	1.8	10
155	Management of Cryptococcosis: How Are We Doing?. PLoS Medicine, 2007, 4, e47.	3.9	9
156	Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. Clinics in Chest Medicine, 2017, 38, 555-573.	0.8	9
157	Fungal Molecular Pathogenesis: What Can It Do and Why Do We Need It?. , 0, , 1-11.		9
158	Fungi that Infect Humans. , 2017, , 811-843.		8
159	Regulatory Mechanism of the Atypical AP-1-Like Transcription Factor Yap1 in Cryptococcus neoformans. MSphere, 2019, 4, .	1.3	8
160	Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam. Medical Mycology, 2020, 58, 1149-1161.	0.3	8
161	The Architecture and Antigenic Composition of the Polysaccharide Capsule. , 0, , 43-54.		8
162	Mycobacterium Avium-intracellulare complex infections in the acquired immunodeficiency syndrome. Journal of Electron Microscopy Technique, 1988, 8, 105-113.	1.1	7

#	ARTICLE	IF	CITATIONS
163	Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 228-233.	1.3	7
164	Complete Genome Sequences for Two <i>Talaromyces marneffeii</i> Clinical Isolates from Northern and Southern Vietnam. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.3	7
165	Uncommon Yeasts and Molds Causing Human Disease. , 2021, , 813-834.		7
166	The longitudinal health economic impact of viral encephalitis in the United States. <i>Journal of Medical Microbiology</i> , 2020, 69, 270-279.	0.7	7
167	The Mating-Type Locus of <i>Cryptococcus</i> : Evolution of Gene Clusters Governing Sex Determination and Sexual Reproduction from the Phylogenomic Perspective. , 0, , 139-149.		7
168	Potential Value of Cefoperazone in Bacterial Meningitis. <i>Drugs</i> , 1981, 22, 60-64.	4.9	6
169	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by <i>Talaromyces marneffeii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
170	Comparison of <i>Cryptococcus gattii</i> /neoformans Species Complex to Related Genera (<i>Papiliotrema</i> and) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i> in Cellular and Infection Microbiology, 2021, 11, 642658.	1.8	6
171	<i>Cryptococcus neoformans</i> : a Sugar-Coated Killer. , 0, , 279-303.		6
172	Invasion of <i>Cryptococcus</i> into the Central Nervous System. , 0, , 465-471.		6
173	Public Health Importance of Cryptococcal Disease: Epidemiology, Burden, and Control. , 0, , 585-593.		6
174	Diagnosis and Laboratory Techniques. , 0, , 381-405.		6
175	Virulence Factors. , 0, , 145-176.		6
176	Editorial: Antifungal Pipeline: Build It Strong; Build It Better!. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 881272.	1.8	6
177	Familial Adenomatous Polyposis Manifesting as <i>Lactococcus</i> Endocarditis: A Case Report and Review of the Association of <i>Lactococcus</i> with Underlying Gastrointestinal Disease. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-5.	0.2	5
178	Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S478-S478.	0.4	5
179	Genomic characterization of recurrent mold infections in thoracic transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12935.	0.7	5
180	1758. Epidemiology of Invasive <i>Mycoplasma</i> and <i>Ureaplasma</i> Infections Early after Lung Transplantation. <i>Open Forum Infectious Diseases</i> , 2019, 6, S646-S646.	0.4	5

#	ARTICLE	IF	CITATIONS
181	The History of Cryptococcus and Cryptococcosis. , 0, , 17-26.		5
182	Diagnostic Approach Based on Capsular Antigen, Capsule Detection, β -Glucan, and DNA Analysis. , 0, , 547-564.		5
183	Population Structure and Ecology of Cryptococcus neoformans and Cryptococcus gattii. , 0, , 97-111.		5
184	Antifungal resistance: the clinical front. Oncology, 2004, 18, 15-22.	0.4	5
185	Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement. Journal of Fungi (Basel, Switzerland), 2022, 8, 212.	1.5	5
186	Efficient, Cost-Effective, High-Throughput, Multilocus Sequencing Typing (MLST) Method, NGMLST, and the Analytical Software Program MLSTEZ. Methods in Molecular Biology, 2017, 1492, 197-202.	0.4	4
187	Feasibility of Neurapheresis as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis. Open Forum Infectious Diseases, 2017, 4, S480-S481.	0.4	4
188	Paediatric bacterial meningitis in the USA: outcomes and healthcare resource utilization of nosocomial versus community-acquired infection. Journal of Medical Microbiology, 2021, 70, .	0.7	4
189	Drug Resistance in Cryptococcosis. , 2017, , 1119-1140.		4
190	Biosynthesis and Genetics of the Cryptococcus Capsule. , 0, , 27-41.		4
191	Cryptococcosis in AIDS. , 0, , 515-525.		4
192	The Cell Wall of Cryptococcus. , 0, , 67-79.		4
193	Prevention of Human Infection. , 0, , 519-530.		4
194	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). Contemporary Clinical Communications, 2021, 24, 100851.	0.5	4
195	What Can the Clinical Mycology Laboratory Do for Clinicians Today and Tomorrow?. Current Clinical Microbiology Reports, 2017, 4, 96-105.	1.8	3
196	QTc Prolongation in Patients Receiving Triazoles and Amiodarone. Open Forum Infectious Diseases, 2017, 4, S84-S84.	0.4	3
197	A Novel Therapeutic Approach for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2016, 3, .	0.4	3
198	A Role for Mating in Cryptococcal Virulence. , 0, , 167-174.		3

#	ARTICLE	IF	CITATIONS
199	Drug Resistance in <i>Cryptococcus</i> : Epidemiology and Molecular Mechanisms. , 0, , 203-216.		3
200	Cryptococcosis in Africa. , 0, , 269-285.		3
201	Cryptococcosis in Asia. , 0, , 287-297.		3
202	The Emergence of <i>Cryptococcus gattii</i> Infections on Vancouver Island and Expansion in the Pacific Northwest. , 0, , 313-325.		3
203	Melanin: Structure, Function, and Biosynthesis in <i>Cryptococcus</i> . , 0, , 55-66.		3
204	Sexual Reproduction of <i>Cryptococcus</i> . , 0, , 81-96.		3
205	Introduction to the Pathogen. , 0, , 1-27.		3
206	Therapy of Cryptococcosis. , 0, , 457-518.		3
207	Specific Immunity and Cytokines. , 0, , 223-269.		3
208	<i>Curvularia alcornii</i> Aortic Pseudoaneurysm Following Aortic Valve Replacement: Case Report and Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab536.	0.4	3
209	Editorial Commentary: Life-saving Antimicrobial Drugs: What Are We Doing to Pricing and Availability?. Clinical Infectious Diseases, 2016, 62, 1569-1570.	2.9	2
210	In Vitro Characterization of the Neurapheresisâ„¢ System for the Treatment of Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, S481-S481.	0.4	2
211	On-demand release of <i>Candida albicans</i> biofilms from urinary catheters by mechanical surface deformation. Biofouling, 2018, 34, 595-604.	0.8	2
212	Sensing Extracellular Signals in <i>Cryptococcus neoformans</i> . , 0, , 175-187.		2
213	Signaling Cascades and Enzymes as <i>Cryptococcus</i> Virulence Factors. , 0, , 217-234.		2
214	Sexual Reproduction of <i>Cryptococcus gattii</i> : a Population Genetics Perspective. , 0, , 299-311.		2
215	Hybridization and Its Importance in the <i>Cryptococcus</i> Species Complex. , 0, , 359-370.		2
216	Cryptococcosis in Experimental Animals: Lessons Learned. , 0, , 473-488.		2

#	ARTICLE	IF	CITATIONS
217	Management of invasive mycoses in hematology patients: current approaches. <i>Oncology</i> , 2004, 18, 5-14.	0.4	2
218	OUP accepted manuscript. <i>Medical Mycology</i> , 2022, , .	0.3	2
219	Transcriptional Profiles Elucidate Differential Host Responses to Infection with <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 430.	1.5	2
220	IRIS and Fungal Infections: What Have We Learned?. <i>Current Fungal Infection Reports</i> , 2012, 6, 1-10.	0.9	1
221	Reply to ArgÃ¼elles. <i>Virulence</i> , 2017, 8, 239-239.	1.8	1
222	Curious Crosses: Injection-Induced Lesions. <i>American Journal of Medicine</i> , 2017, 130, 31-33.	0.6	1
223	Invasive Fungal Disease in the Transplant Population: An Overview. , 2019, , 519-541.		1
224	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27â€“30, 2018, Big Sky, Montana, a proposed global research agenda. <i>Medical Mycology</i> , 2020, 58, 569-578.	0.3	1
225	Black mold takes hold and story told. <i>Medical Mycology Case Reports</i> , 2020, 29, 12-14.	0.7	1
226	Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States. <i>Neurology: Clinical Practice</i> , 2021, 11, 117-126.	0.8	1
227	Reply to Day et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 1627-1628.	1.9	1
228	<i>Cryptococcus</i> Interactions with Innate Cytotoxic Lymphocytes. , 0, , 417-427.		1
229	<i>Cryptococcosis</i> in Transplant Recipients. , 0, , 505-514.		1
230	Vaccines and Antibody Therapies from <i>Cryptococcus neoformans</i> to Melanoma. , 0, , 537-546.		1
231	Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.. <i>Blood</i> , 2006, 108, 3311-3311.	0.6	1
232	Antifungal pharmacotherapy for invasive mould infections. , 0, .		1
233	G-Protein Signaling Pathways: Regulating Morphogenesis and Virulence of <i>Cryptococcus</i> . , 0, , 151-165.		1
234	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1

#	ARTICLE	IF	CITATIONS
235	Animal Models and Veterinary Aspects of Cryptococcosis. , 0, , 325-350.		1
236	Intracellular Replication and Exit Strategies. , 0, , 441-450.		1
237	Use of newer antifungal therapies in clinical practice: what do the data tell us?. Oncology, 2004, 18, 15-23.	0.4	1
238	Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients. Expert Opinion on Orphan Drugs, 2014, 2, 245-257.	0.5	0
239	On-Demand Release of Candida albicans Biofilms From Urinary Catheters by Mechanical Surface Deformation. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
240	Identification of Host-Derived Biomarker Signatures in Cryptococcal Infection. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
241	Dosing Voriconazole in Obese Patients. Open Forum Infectious Diseases, 2017, 4, S292-S293.	0.4	0
242	2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes. Open Forum Infectious Diseases, 2019, 6, S715-S715.	0.4	0
243	Fungal Infections of the Central Nervous System. , 2021, , 803-819.		0
244	Tissue Responses and Special Topics in Immunity. , 0, , 271-324.		0
245	Virulence Mechanisms of Cryptococcus gattii: Convergence and Divergence. , 0, , 189-201.		0
246	Acquired Humoral Immunity to Cryptococcus neoformans. , 0, , 397-408.		0
247	The Interaction of Cryptococcus neoformans with Host MacroPhages and Neutrophils. , 0, , 371-385.		0
248	Pulmonary Innate and Adaptive Defenses against Cryptococcus. , 0, , 451-464.		0
249	Physical Defenses and Nonspecific Immunity. , 0, , 177-222.		0
250	Management of phaeohyphomycosis. , 2019, , 337-345.		0
251	Management of mucormycoses. , 2019, , 357-362.		0
252	Management of cryptococcosis. , 2019, , 301-315.		0

#	ARTICLE	IF	CITATIONS
253	168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of <i>Cryptococcus</i> Meningitis. Open Forum Infectious Diseases, 2020, 7, S213-S213.	0.4	0